Sunday, December 05, 2021 11:19:23 AM
""Remdesivir, known also by its brand name "Veklury," is normally used for adults and children over 12 requiring hospitalization for covid-19, and is normally given in a vein by intravenous (IV) infusion one time each day for up to 10 days."
I am of the opinion that the FDA required IPIX to conduct the trial at less than the dosage we requested, but now I find out that we were only giving out the lower range of the DOSINGS that Rem.... is given -- so where in reality is the apples to apples comparison of IPIX to Rems....? "
For the benefit of the person making the comment and noting that the article quoted said "for up to 10 days":
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Conclusions: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined.
https://pubmed.ncbi.nlm.nih.gov/32459919/
What the commenter described as "the lower range of the DOSINGS that Rem.... is given", which is actually the duration of dosings and not the amount, seems to be the Standard of Care duration. If not, I believe it would have been improper to use it as the SOC in the B-CV trial.
Again, my post is directed to someone who commented on your link and not to you. Obviously (you posted the link without comment).
As my dear old grandfather Litvak said (just before they swung the trap), he said "You can't cheat an honest man. Never give a sucker an even break or smarten up a chump."
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM